Guo et al. (7) found that the Axl inhibitor R428 inhibited tumor growth of subcutaneously implanted murine 4T1 breast cancer cells and intra-peritoneally implanted murine ID8 ovarian cancer cells by activating CD4+ and CD8+ T cells. Here, CD8A is linked to ovarian carcinoma.